Navigation Links
Melanoma treatment options 1 step closer
Date:10/20/2009

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

U of A chemistry professor Dennis Hall said after three years of work, his research team has successfully produced the substance called Palmerolide A.

"The potency of palmerolide is exceptional and melanoma is a very aggressive cancer for which there is almost no chemotherapeutic recourse," said Hall. "Natural substances like palmerolide offer real hope for such treatments.

"Current chemotherapy as an overall strategy is not very effective in treating melanoma. Less than a quarter of patients respond to chemotherapy and it typically only works for less than a year, and it has little to no effect on survival time. Palmerolide A as a targeted therapy may prove to be more effective [for treatment] with less toxicity," said Hall.

"One of the problems with most cancer drugs is the lack of selectivity for cancer cells versus normal cells. Preliminary data for Palmerolide A looks very promising in terms of solving this issue," he said.

"For commercialization, the structure needs to be made more 'drug-like;' smaller and more water-soluble, while preserving the potency," said Hall, who is optimistic that his U of A team is moving forward in the race to develop a treatment for melanoma.


'/>"/>

Contact: Wanda Vivequin
wanda.vivequin@ualberta.ca
780-492-4073
University of Alberta
Source:Eurekalert

Page: 1

Related biology news :

1. Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
2. Study shows cancer vaccines led to long-term survival for patients with metastatic melanoma
3. Zebrafish provide a model for cancerous melanoma in humans
4. New method for detection of phosphoproteins reveals regulator of melanoma invasion
5. NYU Langone Medical Center researchers find micro RNA plays a key role in melanoma metastasis
6. Stress may hasten the growth of melanoma tumors
7. GUMC researchers find gene function lost in melanoma and glioblastoma
8. Vitiligo skin disorder could yield clues in fight against melanoma
9. Variant of vitamin D receptor gene linked to melanoma risk
10. As rates rise, researchers find better way to identify melanoma
11. New study shows Dermytol produces pronounced decrease in malignant melanoma tumor volume
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... its Chairman and CEO, Jim Joyce . ... Conference last Saturday, Bill Gates warned world ... people than nuclear weapons. Mr. Gates expressed his concern, ... agencies, that scientific terrorists have access to the necessary ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... unaudited financial results for the third quarter and first ... 2016. Third Quarter of Fiscal 2017 Highlights ... fiscal 2017 increased by 18.6% to RMB200.9 million ($28.9 ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
Breaking Biology Technology: